2023-10-21 07:00:00
Environment: Danish manufacturers ahead of decarbonization
Created in 2019, theFranco-Danish Health Alliance presented the results of its second study measuring its economic and environmental impact on French territory. The association brings together five subsidiaries of large Danish groups with industrial facilities firmly established in France: ALK, Coloplast, Leo Pharma, Lundbeck and Novo Nordisk. The alliance thus employs nearly 4,000 people in France, including 1,500 in production, for an impact on French GDP of €1.2 billion. A figure up slightly compared to the previous study.
But this year, the Alliance wanted to highlight its environmental impact. “In terms of possible trajectory on carbon emissions, the companies in the Alliance[er]are at -45% by 2030 (compared to 2015) while the French pharmaceutical industry is[will be]at -33%”notes Marie-Laetitia des Robert, founding director of Randea, in charge of the study.
VOS INDICES
source
“Our Danish industries are a model of industrial decarbonization, we started on these subjects earlier”, welcomes Nicolas Dufourt, general director of ALK France. By highlighting this economic weight and this pioneering role in decarbonization, the companies in the Alliance are calling for greater consideration of environmental and industrial criteria in medicines policy. A plea on which the Franco-Danish Alliance joins other organizations such as Leem or the G5 Santé.
Oncology: Amgen to collaborate with Gustave Roussy
Following the founding of the Amgen Partners of Choice (APoC) network, Amgen will join forces with Gustave Roussythe first cancer center in Europe, and seven other world-renowned research centers.
Ultimately, the objective is to accelerate the transition of early R&D research to the clinic, as Jean-Charles Soria, Amgen’s global vice president of R&D Oncology, indicated: “Through the Amgen Partners of Choice network, we hope to foster earlier, deeper and more frequent academic collaborations to accelerate progress for patients.” »
The therapeutic area concerned is oncology, in particular thoracic, gastrointestinal and genitourinary cancers which are still difficult to treat. To do this, APoC will offer a platform and an entire ecosystem through which researchers, clinicians and manufacturers will be able to exchange their expertise and their research projects. These exchanges might take place during a congress, organized by APoC, twice a year.
Innovation: France Biotech wants to promote mentoring
L’association France Biotech launched the second edition of its mentoring program. The initiative aims to promote interactions between executives from the pharmaceutical industry and biotech companies, a key issue for the proper development of the latter. France Biotech had carried out a first pilot project with Ipsen, in 2021. A successful trial balloon, since the association is renewing this program with, this time, three French laboratories involved: Ipsen, joined by Servier and BioMérieux.
“We had very good feedback from the ten pairs of “mentors/mentees” during the first edition”welcomes Françoise Vincent Larrodé, co-coordinator of the Human Resources commission of France Biotech. “The pharmaceutical world was able to discover that of entrepreneurship in biotechnology with its constraints and its particularities (the search for financing, the positioning of the drug candidate, the strategy, clinical studies and access to the market). The discussions were very fruitful on the structuring of the company, the optimization of development plans, the implementation of processes to promote operations”she recalled.
Selected for you
1697891383
#France #Biotech #FrancoDanish #Health #Alliance #Amgen
